Cargando…
Viabahn for femoropopliteal in-stent restenosis
BACKGROUND AND OBJECTIVES: In-stent restenosis in the femoropopliteal artery is common (20%–40%). Treatment of in-stent restenosis is challenged by poor patency rate. An ePTFE-covered stent-graft (Viabahn) is inert with a very small pore size that does not allow for significant tissue in-growth. Use...
Autores principales: | Al Shammeri, Owayed, Bitar, Fahad, Ghitelman, Jaime, Soukas, Peter A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081106/ https://www.ncbi.nlm.nih.gov/pubmed/23396019 http://dx.doi.org/10.5144/0256-4947.2012.575 |
Ejemplares similares
-
Treatment of Femoropopliteal Artery In-stent Restenosis
por: Kim, Wonho, et al.
Publicado: (2018) -
Femoropopliteal Artery Stent Fracture with Recurrent In-Stent Reocclusion and Aneurysm Formation: Successful Treatment with Self-Expandable Viabahn Endoprosthesis
por: Lee, Yong-Joon, et al.
Publicado: (2015) -
Clinical Impact of Additional Cilostazol Treatment on Restenosis Risk following Heparin-Bonded Stent Graft Implantation: Sub-Analysis from the Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study
por: Tobita, Kazuki, et al.
Publicado: (2023) -
Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry
por: Vu, Michael H., et al.
Publicado: (2022) -
Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions
por: Horie, Kazunori, et al.
Publicado: (2021)